FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to ophthalmology. A method for increasing the stability of a prostaglandin composition comprising prostaglandin, a preserving agent and pharmaceutically acceptable excipients, wherein the method comprises a stage whereat: the prostaglandin composition specified in a group consisting of Travoprost, Latanoprost, Bimatoprost and Tafluprost is packaged in a reusable low-density polyethylene container made of a low-density polyethylene wherein said low-density polyethylene container represents a low-density polyethylene bottle prepared with the use of blow-fill-seal technology, wherein low-density polyethylene resin is specified in a group consisting of Purell PE 1810 E, Purell PE 1840 H, Purell PE 3020 D, Purell PE 3040 D, Purell PE 3220 D.
EFFECT: group of inventions provides the local reusable ocular administration, the stability of the composition at room temperature up to 25°C for more than twelve months.
18 cl, 5 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION OF TAFLUPROST | 2021 |
|
RU2761625C2 |
OIL-IN-WATER OPHTHALMIC EMULSIONS CONTAINING PROSTAGLANDINS | 2008 |
|
RU2460516C2 |
PROSTAGLANDIN F2 ALPHA AND ITS ANALOGUES FOR TREATING ATROPHIC SKIN SCARRING | 2014 |
|
RU2690183C2 |
OPHTHALMIC GEL BIMATOPROST, WHICH IS APPLIED IN FORM OF DROPS | 2016 |
|
RU2698456C2 |
OPHTHALMIC COMPOSITIONS CONTAINING PROSTAMIDE RELEASING NITROGEN OXIDE | 2019 |
|
RU2781022C2 |
INTRAOCULAR SYSTEMS OF SUSTAINED-RELEASE DRUG DELIVERY AND METHOD OF TREATING OPHTHALMIC DISEASES | 2010 |
|
RU2532333C2 |
INTRACHAMBER IMPLANTS WITH PROLONGED RELEASE OF THERAPEUTIC AGENT | 2011 |
|
RU2565445C2 |
OPHTHALMIC PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2734344C2 |
COMPOSITION IN THE FORM OF EYE DROPS TO DECREASE INTRAOCULAR PRESSURE | 2017 |
|
RU2772230C2 |
COMPOSITIONS AND METHODS FOR TOPICAL PROSTAGLANDINS DELIVERY TO SUBCUTANEOUS FAT | 2014 |
|
RU2635864C2 |
Authors
Dates
2013-05-27—Published
2010-02-18—Filed